About vaccines

A group of researchers from Maccabi Healthcare Services performed a retrospective cohort study to determine vaccine effectiveness of a third dose. // 8.11.2021

A group of multi-national researchers has expanded on previous research to conduct a preliminary evaluation of the effectiveness of the Ad26.COV2.S vaccine via HER data. // 8.11.2021

A new study posted in the bioRxiv* preprint server used mouse models to investigate how mRNA vaccines elicit a rapid antibody response. Their findings show two different mRNA vaccines successfully boost antibody levels — IL-5, IL-6, and MCP-1 —5 days after administration. // 7.11.2021

A new study published in the preprint bioRxiv* server suggests vaccination helps to inflate the number of somatic hypermutations acquired by B cells. The increase in somatic hypermutations allows for an accumulation of highly matured bone marrow plasma cells. // 8.11.2021

The U.S. CDC reports the observed efficacy among the immunocompromised population following vaccination with mRNA vaccines against SARS-CoV-2. // 7.11.2021

A recent study assesses the boost in antibodies against SARS-CoV-2)variants post-vaccination in plasma samples from previously infected COVID-19 patients. // 7.11.2021

We report SARS-CoV-2 vaccine effectiveness against infection (VE-I) and death (VE-D) by vaccine type (n = 780,225) in the Veterans Health Administration, covering 2.7% of the U.S. population. // 4.11.2021

This case-control study explores the association between vaccination with mRNA COVID-19 vaccines and hospitalization for COVID-19, and, among patients hospitalized with COVID-19, the association with progression to critical disease in adults from 18 US states. //4.11.2021

A new study concludes that a COVID-19 mRNA vaccine is around five times more effective at preventing hospitalization than a previous SARS-CoV-2 infection. // 5.11.2021

A new preprint describes the protective efficacy of memory T-cells developed in response to the viral antigen, which could offer long-term immunity. // 4.11.2021

A new study describes the results of the safety and efficacy phase trials of a new COVID-19 vaccine from Cuba. // 4.11.2021

The vaccine also led to lower risk of hospitalizations and ICU admissions // 3.11.2021

Researchers review the heterologous immunity to coronaviruses and the extent of immune cross-reactivity against SARS-CoV-2. // 4.11.2021

The study, recently published in The Journal of the American Medical Association, deduced that previous SARS-CoV-2 infection is associated with a statistically significant reduced hazard of breakthrough infection among recipients of both the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) vaccines. // 3.11.2021

A new study examined SARS-CoV-2 spike IgG antibodies in a longitudinal cohort, comparing antibody durability in individuals who received an mRNA SARS-CoV-2 vaccine with or without prior SARS-CoV-2 infection. // 3.11.2021

Researchers sought to analyze immune responses after homologous vaccinations or after heterologous Vector/mRNA vaccinations, with respect to anti-COVID-19 immune responses and the development of autoantibodies. // 3.11.2021

An overview of the PIENTER-Corona (PiCo) study, which is a Dutch nationwide efficacy comparison study on four different COVID-19 vaccines. // 2.11.2021

In this study, the researchers observed a significant effect of time of vaccination on the vaccine-induced SARS-CoV-2 immunity, which was estimated by measuring the anti-Spike antibody levels. // 2.11.2021

A recent study has evaluated vaccine-induced humoral and cellular immunity against SARS-CoV-2 six months post BNT162b2 (Pfizer-BioNTech) vaccination. // 2.11.2021

The politicization of covid vaccines — and, well, just about everything else having to do with the pandemic — has led to confusion, if not utter fatigue. // 2.11.2021

A team of scientists from Israel and the USA has recently examined the efficacy of coronavirus disease 2019 (COVID-19) vaccination in reducing the death risk among people aged 70 years and above. They observe that despite government-imparted relaxation on non-pharmaceutical control measures, the vaccine saved more lives than expected by individual-level vaccine efficacy. // 1.11.2021

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response. // 1.11.2021

Researchers from the UK used EAVE II, an individual-level, national surveillance system, to determine the frequency of COVID-19-related fatalities among fully vaccinated individuals and to define the clinical and demographic characteristics of COVID-19 deaths in fully vaccinated individuals since the beginning of the COVID-19 vaccination program in Scotland. // 1.11.2021

A new study posted to the medRxiv* preprint server, analyzed safety data from over 298 million mRNA COVID-19 vaccines administered in the first six months after the U.S. began its vaccination campaign. // 1.11.2021 ”Compared to expected background rates of death from all causes per million vaccinated persons, deaths reported to VAERS following mRNA vaccination were consistently 15-30 times less frequent within 7 days of vaccination, and 50 times less frequent within 42 days of vaccination, by age,”

Research published in the journal Nature Medicine suggests a risk for neurological complications after the first shot of a COVID-19 vaccine. However, the likelihood of developing neurological complications remains far greater among people infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 31.10.2021

The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the third dose of the Pfizer/BioNTech BNT162B2 vaccine against the Delta variant of SARS-CoV-2. // 30.10.2021

A new study compares healthcare workers who underwent homologous Ad26.COV2.S booster vaccination to those who underwent heterologous boosting. // 28.10.2021

In some patients, the immune system responds poorly to the second vaccination dose. This changes with the third shot. // 28.10.2021

A new study examined protection against symptomatic coronavirus disease 2019 (COVID-19) from non-Delta variants using data from randomized control trials. // 28.10.2021

Researchers investigated the neutralizing antibody response that different mRNA vaccines induce in both previously convalescent and SARS-CoV-2 naïve individuals. // 28.10.2021